These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 27773786)

  • 1. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
    Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
    Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
    Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
    Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.
    Oprescu B; Raduna O; Mihaicuta S; Frent S
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541113
    [No Abstract]   [Full Text] [Related]  

  • 6. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
    Siva R; Green RH; Brightling CE; Shelley M; Hargadon B; McKenna S; Monteiro W; Berry M; Parker D; Wardlaw AJ; Pavord ID
    Eur Respir J; 2007 May; 29(5):906-13. PubMed ID: 17301099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
    Matera MG; Rogliani P; Calzetta L; Cazzola M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 9. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
    Barnes PJ
    J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agents against cytokine synthesis or receptors.
    Yamagata T; Ichinose M
    Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.
    Mkorombindo T; Dransfield MT
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1779-1787. PubMed ID: 31496677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting IL-5 in COPD.
    Narendra DK; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1045-1051. PubMed ID: 31190789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
    Sahota J; Robinson DS
    Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
    Gerday S; Graff S; Moermans C; Guissard F; Paulus V; Henket M; Louis R; Schleich F
    Thorax; 2023 Nov; 78(11):1138-1141. PubMed ID: 37657926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
    Bel EH; Ten Brinke A
    Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
    J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations.
    Salciccioli JD; Israel E
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):693-708. PubMed ID: 39389718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.